AstraZeneca and Bristol Myers Squibb rumored to be in talks for a major merger

Over the weekend, reports emerged that AstraZeneca and Bristol Myers Squibb were reportedly discussing a possible merger.

Industry observers note that such a combination would create one of the largest pharmaceutical entities, potentially reshaping the competitive landscape.

The speculation comes amid broader conversations about a resurgence of big-pharma megamergers, though no formal agreement has been announced.

Analysts caution that regulatory scrutiny and integration challenges could affect any eventual deal, and investors are watching closely.